|
1
|
Ghisi GL, Durieux A, Pinho R and Benetti
M: Physical exercise and endothelial dysfunction. Arq Bras Cardiol.
95:e130–e137. 2010.(In English, Portuguese and Spanish).
|
|
2
|
Gao X, Martinez-Lemus LA and Zhang C:
Endothelium-derived hyperpolarizing factor and diabetes. World J
Cardiol. 3:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oelze M, Schuhmacher S and Daiber A:
Organic nitrates and nitrate resistance in diabetes: the role of
vascular dysfunction and oxidative stress with emphasis on
antioxidant properties of pentaerithrityl tetranitrate. Exp
Diabetes Res. 2010:2131762010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sandoo A, van Zanten JJ, Metsios GS,
Carroll D and Kitas GD: The endothelium and its role in regulating
vascular tone. Open Cardiovasc Med J. 4:302–312. 2010.PubMed/NCBI
|
|
5
|
Franses JW, Baker AB, Chitalia VC and
Edelman ER: Stromal endothelial cells directly influence cancer
progression. Sci Transl Med. 3:66ra52011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barton M: Prevention and endothelial
therapy of coronary artery disease. Curr Opin Pharmacol.
13:226–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mount DB: The kidney in hyperuricemia and
gout. Curr Opin Nephrol Hypertens. 22:216–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bakris GL, Doghramji PP, Keenan RT and
Silber SH: CaseBook challenges: Managing gout, hyperuricemia and
comorbidities - dialogue with the experts. Am J Med. 127:S12014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sautner J, Gruber J, Herold M, Zwerina J
and Leeb BF: Austrian 3e-recommendations for diagnosis and
management of gout 2013. Wien Klin Wochenschr. 126:79–89. 2014.(In
German).
|
|
10
|
Maruhashi T, Nakashima A, Soga J, et al:
Hyperuricemia is independently associated with endothelial
dysfunction in postmenopausal women but not in premenopausal women.
BMJ Open. 3:e0036592013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Zhu J, Gao L, et al: Hyperuricemia
as an independent predictor of vascular complications and mortality
in type 2 diabetes patients: a meta-analysis. PLoS One.
8:e782062013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ndrepepa G, Cassese S, Braun S, et al: A
gender-specific analysis of association between hyperuricaemia and
cardiovascular events in patients with coronary artery disease.
Nutr Metab Cardiovasc Dis. 23:1195–1201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan Y and Chen YE: Combined therapeutic
strategy to improve vascular endothelial function after
implantation of sirolimus-eluting stents. Circ J. 75:1051–1052.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghaffari N, Ball C, Kennedy JA, Stafford I
and Beltrame JF: Acute modulation of vasoconstrictor responses by
pravastatin in small vessels. Circ J. 75:1506–1514. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Foody JM, Toth PP, Tomassini JE, et al:
Changes in LDL-C levels and goal attainment associated with
addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin
compared with titrating statin monotherapy. Vasc Health Risk Manag.
9:719–727. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maji D, Shaikh S, Solanki D and Gaurav K:
Safety of statins. Indian J Endocrinol Metab. 17:636–646. 2013.
View Article : Google Scholar
|
|
17
|
Kones R: Rosuvastatin, inflammation,
C-reactive protein, JUPITER, and primary prevention of
cardiovascular disease - a perspective. Drug Des Devel Ther.
4:383–413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Savoia C, Sisalli MJ, Di Renzo G,
Annunziato L and Scorziello A: Rosuvastatin-induced neuroprotection
in cortical neurons exposed to OGD/reoxygenation is due to nitric
oxide inhibition and ERK1/2 pathway activation. Int J Physiol
Pathophysiol Pharmacol. 3:57–64. 2011.PubMed/NCBI
|
|
19
|
Chen GL, Zhang QL, Ma XQ and Xu SY:
Hyperuricemia model induced by yeast in mice. Zhongguo Yao Li Xue
Tong Bao. 19:467–469. 2003.(In Chinese).
|
|
20
|
Guide for the care and use of laboratory
animals. 8th Edition. The National Academies Press; Washington,
D.C, USA: pp. 11–35. 2011
|
|
21
|
Xilifu D, Zhao P, Song LJ, Rehemu N and
Zhang XY: Development of secondary cardiovascular disease in
hyperuricemia model rats induced by yeast extract combined with
oteracil potassium. Zhongguo Zuzhi Gongcheng Yanjiu. 16:1994–1998.
2012.
|
|
22
|
Tomiyama H, Higashi Y, Takase B, et al:
Relationships among hyperuricemia, metabolic syndrome, and
endothelial function. Am J Hypertens. 24:770–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwa KS, Chung DM, Chung YC and Chun HK:
Hypouricemic effects of anthocyanin extracts of purple sweet potato
on potassium oxonate-induced hyperuricemia in mice. Phytother Res.
25:1415–1417. 2011.PubMed/NCBI
|
|
24
|
Wang Y and Bao X: Effects of uric acid on
endothelial dysfunction in early chronic kidney disease and its
mechanisms. Eur J Med Res. 18:262013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwartz IF, Grupper A, Chernichovski T,
et al: Hyperuricemia attenuates aortic nitric oxide generation,
through inhibition of arginine transport, in rats. J Vasc Res.
48:252–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zharikov SI, Swenson ER, Lanaspa M, et al:
Could uric acid be a modifiable risk factor in subjects with
pulmonary hypertension? Med Hypotheses. 74:1069–1074. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsai IJ, Croft KD, Puddey IB, Beilin LJ
and Barden A: 20-Hydroxyeicosatetraenoic acid synthesis is
increased in human neutrophils and platelets by angiotensin II and
endothelin-1. Am J Physiol Heart Circ Physiol. 300:H1194–H1200.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lagerqvist EL, Finnin BA, Pouton CW and
Haynes JM: Endothelin-1 and angiotensin II modulate rate and
contraction amplitude in a subpopulation of mouse embryonic stem
cell-derived cardiomyocyte-containing bodies. Stem Cell Res.
6:23–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Papageorgiou N, Tousoulis D, Antoniades C,
Giolis A, Briasoulis A and Stefanadis C: The impact of statin
administration in acute coronary syndromes. Hellenic J Cardiol.
51:250–261. 2010.PubMed/NCBI
|
|
30
|
Doi T, Sakoda T, Akagami T, et al:
Aldosterone induces interleukin-18 through endothelin-1,
angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J
Physiol Heart Circ Physiol. 295:H1279–H1287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takahashi Y, Satoh M, Tabuchi T and
Nakamura M: Prospective, randomized, single-blind comparison of
effects of 6 months’ treatment with atorvastatin versus pravastatin
on leptin and angiogenic factors in patients with coronary artery
disease. Heart Vessels. 27:337–343. 2012.
|
|
32
|
Ali F, Zakkar M, Karu K, et al: Induction
of the cytoprotective enzyme heme oxygenase-1 by statins is
enhanced in vascular endothelium exposed to laminar shear stress
and impaired by disturbed flow. J Biol Chem. 284:18882–18892. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lardizabal JA and Deedwania PC: The
anti-ischemic and anti-anginal properties of statins. Curr
Atheroscler Rep. 13:43–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pasceri V, Willerson JT and Yeh ET: Direct
proinflammatory effect of C-reactive protein on human endothelial
cells. Circulation. 102:2165–2168. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Datar R1, Kaesemeyer WH, Chandra S, et al:
Acute activation of eNOS by statins involves scavenger receptor-B1,
G protein subunit Gi, phospholipase C and calcium influx. Br J
Pharmacol. 160:1765–1772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miyata R, Hiraiwa K, Cheng JC, et al:
Statins attenuate the development of atherosclerosis and
endothelial dysfunction induced by exposure to urban particulate
matter (PM10). Toxicol Appl Pharmacol. 272:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meda C, Plank C, Mykhaylyk O, Schmidt K
and Mayer B: Effects of statins on nitric oxide/cGMP signaling in
human umbilical vein endothelial cells. Pharmacol Rep. 62:100–112.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Q and Liao JK: Pleiotropic effects of
statins. Basic research and clinical perspectives. Circ J.
74:818–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu ZF, Yang C, Qiu X, Chen Y, Kong LD and
Wang MS: The influence of daphnin on rats suffering hyperuricemia.
Zhongguo Yi Ke Da Xue Xue Bao. 33:142–145. 2002.(In Chinese).
|
